Nevakar & Endo Enter Exclusive Licensing Agreement for Multiple 505(b)(2) Injectable Products

Nevakar Inc. recently announced it entered into an exclusive licensing agreement with Endo International plc’s subsidiary, Endo Ventures Limited, for the development of five differentiated, sterile injectable products in the US and Canada. Pursuant to the agreement, Nevakar will develop and seek US FDA approval for these products, and Endo’s Par Pharmaceutical Sterile Products division will launch and distribute the products upon approval.

“We are pleased to establish this partnership with Endo, a respected pharmaceutical company with a significant and growing presence in sterile and critical care products. This agreement validates Nevakar’s strong pipeline and business model and furthers our mission to develop innovative pharmaceutical products that improve patient care and quality of life,” said Navneet Puri, PhD, Founder, President and Chief Executive Officer of Nevakar.

“This important strategic initiative provides us with products that align well with our goal of expanding our sterile injectables business and adding more complex 505(b)(2) products into our pipeline. If approved, these drugs will benefit patients by providing new treatment options in the hospital and critical care environment,” added Paul Campanelli, President and CEO of Endo. “We look forward to once again working with Dr. Navneet Puri and the Nevakar team to bring these products to market.”

Par Pharmaceutical currently markets several products that were developed by InnoPharma, a company which was also founded by Dr. Navneet Puri and subsequently sold to Pfizer in 2014.

Nevakar Inc. is growing as a fully integrated specialty pharmaceutical company with an extensive portfolio of products in the ophthalmic and injectable areas. Founded in 2015, and headquartered in Bridgewater NJ, the company is focused on developing and commercializing innovative products to address unmet medical needs, thereby improving patient care and quality of life. Nevakar utilizes the 505(b)(2) regulatory pathway, along with its proven expertise in the development of novel and proprietary sterile pharmaceutical products to identify, develop, and obtain regulatory approval for its products. Additional information is available at

Endo International plc (NASDAQ: ENDP) is a highly focused generics and specialty branded pharmaceutical company delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA. Learn more at

Par Pharmaceutical, headquartered in Chestnut Ridge, NY, develops, manufactures and markets safe, innovative and cost-effective generic pharmaceutical products that help improve patient quality of life. Par, among the top leaders in the U.S. generics industry, possesses a portfolio that includes sterile injectables, alternative dosage forms and many other differentiated products. Par is advancing a research and development (R&D) pipeline of approximately 200 potential new products.  Par is an operating company of Endo International plc. Learn more at